Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM37GYA)

• Drug Name: BzATP Drug Info
• Synonyms: BzATP; 3'-O-(4-Benzoyl)benzoyl ATP; 3'-O-(4-Benzoylbenzoyl)ATP; 3'-O-(4-Benzoyl)benzoyladenosine 5'-triphosphate; UNII-4P5DXU1F8Q; 81790-82-1; 4P5DXU1F8Q; CHEBI:34316; Adenosine 5'-(tetrahydrogen triphosphate), 3'-(4-benzoylbenzoate); C24H24N5O15P3; ATP, Bz; AC1L3GPW; AC1Q6S3N; SCHEMBL3682844; GTPL1757; CHEMBL2407634; BDBM86488; ZINC8295154; 3'-o-(4-benzoylbenzoyl)adenosine 5'-(tetrahydrogen triphosphate); LS-177651; CAS_81790-82-1; C13744; 3'-O-(4-benzoylbenzoyl)adenosine 5'-triphosphate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 115205
  ChEBI ID: CHEBI:34316
  CAS Number: CAS 81790-82-1
  TTD Drug ID: DM37GYA

Molecule-Related Drug Atlas

Drug(s) Targeting P2X purinoceptor 3 (P2RX3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gefapixant	DM4GWL7	Cough	MD12	Phase 3	[5]
BAY-1902607	DMYSQMW	Cough	MD12	Phase 2	[5]
BAY 1902607	DMFA4CK	Cough	MD12	Phase 1/2	[5]
AF-130	DM8LG2I	Hypertension	BA00-BA04	Phase 1	[6]
BAY-1817080	DMNL5G7	Endometriosis	GA10	Phase 1	[5]
BAY 1817080	DMF9ALP	Cough	MD12	Phase 1	[7]
TNP-ATP	DMVZY0X	Discovery agent	N.A.	Investigative	[8]
ISOPPADS	DMWI0M8	Discovery agent	N.A.	Investigative	[9]
LVAYPWT	DMIO405	Discovery agent	N.A.	Investigative	[10]
MK-3901	DM5EQ7F	Pain	MG30-MG3Z	Investigative	[3]

Drug(s) Targeting P2X purinoceptor 1 (P2RX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-betagamma-meATP	DMTNQCE	Discovery agent	N.A.	Investigative	[2]
TNP-ATP	DMVZY0X	Discovery agent	N.A.	Investigative	[8]
MRS 2219	DM7IK68	Discovery agent	N.A.	Investigative	[11]
NF023	DMJ4GO9	Discovery agent	N.A.	Investigative	[2]
NF449	DM816Z2	Discovery agent	N.A.	Investigative	[12]
Ip5I	DMB2YXN	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting P2Y purinoceptor 11 (P2RY11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[13]
2MeSATP	DMUE0W6	Discovery agent	N.A.	Investigative	[4]
ATPgammaS	DMXHQIN	Discovery agent	N.A.	Investigative	[4]
NAADP	DM51DW6	Discovery agent	N.A.	Investigative	[14]
NF546	DMPZB31	Discovery agent	N.A.	Investigative	[15]
dATP	DMMXFBJ	Discovery agent	N.A.	Investigative	[4]
NF157	DMGMH8T	Discovery agent	N.A.	Investigative	[16]
NF340	DMPSXR8	Discovery agent	N.A.	Investigative	[17]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2X purinoceptor 1 (P2RX1)	TTJW7B3	P2RX1_HUMAN	Agonist	[2]
P2X purinoceptor 3 (P2RX3)	TT2THBD	P2RX3_HUMAN	Agonist	[3]
P2Y purinoceptor 11 (P2RY11)	TTYXPCO	P2Y11_HUMAN	Agonist	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1757).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480).
• [4] Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206.
• [5] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240.
• [8] Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
• [9] Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9.
• [10] Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7.
• [11] A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem. 1998 Jun 18;41(13):2201-6.
• [12] Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004 Apr;39(4):345-57.
• [13] Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling. Mol Pharmacol. 2003 Jun;63(6):1356-63.
• [14] NAADP+ is an agonist of the human P2Y11 purinergic receptor. Cell Calcium. 2008 Apr;43(4):344-55.
• [15] NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther. 2010 Jan;332(1):238-47.
• [16] Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem. 2005 Nov 3;48(22):7040-8.
• [17] Invited Lectures : Overviews Purinergic signalling: past, present and future. Purinergic Signal. 2006 May;2(1):1-324.